Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2524

Sort by

Sort Order Select

Journal Articles

Occupy BTK: the key to controlling CLL

Philip A. Thompson

Blood (2020) 136 (1): 4–6.

https://doi.org/10.1182/blood.2020005877

Published: 2020

Journal Articles

Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis

Aileen G. Rowan, Richard Dillon, Aviva Witkover, Anat Melamed, Maria-Antonietta Demontis, Nicolas A. Gillet, Liew Jun Mun, Charles R. M. Bangham, Lucy B. Cook, Paul A. Fields, Graham P. Taylor

Blood (2020) 135 (23): 2023–2032.

https://doi.org/10.1182/blood.2019002665

Published: 2020

Includes: Supplemental data

Journal Articles

Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

Biping Deng, BS, MD, Jing Pan, Shuangyou Liu, Yuehui Lin, Zhaoli Liu, Yunlong Chen, Xiaoming Qu, Yu 'e Zhang, Zhongxin Zhang, Xuansha Niu, Ming Ma, Tong Wu, MD, Alex Hong Chang, Chunrong Tong

Blood (2019) 134 (Supplement_1): 1957.

https://doi.org/10.1182/blood-2019-126695

Published: 2019

Journal Articles

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Katia Beider, Valeria Voevoda, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Ivetta Danilesko, MD, Ania Hava Grushchenko-Polaq, Olivia Devillers, Idit Wolf, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 1989.

https://doi.org/10.1182/blood-2019-129619

Published: 2019

Journal Articles

Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia

Darina Ocadlikova, PhD, Serenella Casella, Ines Pintao, Elena Adinolfi, Sabina Sangaletti, PhD, Elena De Marchi, Anna Pegoraro, Elisa Orioli, Mario Paolo Colombo, Francesco Di Virgilio, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2332.

https://doi.org/10.1182/blood-2019-126478

Published: 2019

Journal Articles

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Ramon Mohanlal, PhD MD, Douglas W. Blayney, MD, Lan Huang, PhD

Blood (2019) 134 (Supplement_1): 4860.

https://doi.org/10.1182/blood-2019-128563

Published: 2019

Journal Articles

Control of HIV-1 Infection By Ferroportin Q248H Mutation

Namita Kumari, PhD, Seyed Mehdi Nouraie, PhD MD, Hatajai Lassiter, MS, BS, Asrar Ahmad, PhD, Kathryn Anastos, Jason Lazar, Seble Kassaye, Bradley Aouizerat, Audrey French, Stephen Gange, Adaora Adimora, Neale Weitzmann, Margaret Fischl, Mirjam-Colette Kempf, Sergei Nekhai, PhD

Blood (2019) 134 (Supplement_1): 953.

https://doi.org/10.1182/blood-2019-128685

Published: 2019

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 1379.

https://doi.org/10.1182/blood-2019-131348

Published: 2019

Journal Articles

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Tongyuan Xue, MD, Marissa Del Real, PhD, Emanuela Marcucci, Candida Toribio, Sonia Maryam Setayesh, Stephen J Forman, MD, David A Horne, PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 1383.

https://doi.org/10.1182/blood-2019-121486

Published: 2019

Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo E Diaz, MD, Matthew James Butler, MD, Anand Karnad, MD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 1592.

https://doi.org/10.1182/blood-2019-124382

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies

Wen Zhu, Yongwei Zheng, PhD, Mei Yu, PhD, Yaling Wu, Jianhui Wei, Nicholas Schneider, Anand Padmanabhan, MD PhD, Richard H. Aster, MD, Demin Wang, PhD, Renren Wen, PhD

Blood (2019) 134 (Supplement_1): 439.

https://doi.org/10.1182/blood-2019-126097

Published: 2019

Journal Articles

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Qing Li, MD, Yunfan Yang, MD, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 536.

https://doi.org/10.1182/blood-2019-123876

Published: 2019

Journal Articles

FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance

Devi Gunasekera, MBBS, Pooja Vir, PhD, Ahmad Faisal Karim, PhD, Margaret V. Ragni, MD MPH, Elizabeth P. Merricks, PhD, Timothy C. Nichols, MD, Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 630.

https://doi.org/10.1182/blood-2019-124880

Published: 2019

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Breakthroughs in Preclinical Development of Ataluren (PTC124) As Therapeutic Option for Patients Affected By Shwachman-Diamond Syndrome: Towards the First Clinical Trial

Valentino Bezzerri, PhD, Antonio Vella, PhD, Elisabetta D'Aversa, PhD, Martina Api, PhD, Marisole Allegri, MSc, Elena Marinelli Busilacchi, PhD, Giovanna D'Amico, BSc, PhD MSc, Roberto Gambari, PhD, Claudio Sorio, MD PhD, Benedetta Fabrizzi, MD, Vincenzo Bronte, MD, Antonella Poloni, PhD MD, Monica Borgatti, PhD, Marco Cipolli, MD

Blood (2019) 134 (Supplement_1): 451.

https://doi.org/10.1182/blood-2019-127866

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Occupy BTK: the key to controlling CLL

Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis

Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Control of HIV-1 Infection By Ferroportin Q248H Mutation

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Breakthroughs in Preclinical Development of Ataluren (PTC124) As Therapeutic Option for Patients Affected By Shwachman-Diamond Syndrome: Towards the First Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only